Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.77 |
| ▸ | PLK4 | O00444 | 3/20 | 0.71 |
| ▸ | EGFR | P00533 | 3/20 | 0.71 |
| ▸ | LCK | P06239 | 3/20 | 0.71 |
| ▸ | FYN | P06241 | 3/20 | 0.71 |
| ▸ | IGF1R | P08069 | 3/20 | 0.71 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.71 |
| ▸ | FLT3 | P36888 | 3/20 | 0.71 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.71 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.71 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.71 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.71 |
| ▸ | SLK | Q9H2G2 | 3/20 | 0.71 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.71 |
| ▸ | GAK | O14976 | 2/20 | 0.71 |
| ▸ | ERN1 | O75460 | 2/20 | 0.71 |
| ▸ | STK10 | O94804 | 2/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866389 | 0.93 | ALK (0.76) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866311 | 0.91 | ALK (0.84) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866190 | 0.90 | ALK (0.73) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866445 | 0.90 | ALK (0.73) | ALKPLK4EGFRLCKFYN | |
| Hydrochloric Acid SCHEMBL2829175 | 0.90 | ALK (0.82) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL2820888 | 0.90 | ALK (0.86) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866451 | 0.90 | ALK (0.72) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866574 | 0.90 | ALK (0.72) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866294 | 0.89 | ALK (0.71) | ALKPLK4EGFRLCKFYN | |
| SCHEMBL14866454 | 0.89 | ALK (0.71) | ALKPLK4EGFRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885PLK4 173/4885EGFR 2/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | ALK 3/4885PLK4 173/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.